Robert M Gemmill

US Patent:

20020106656, Aug 8, 2002

Filed:

Jul 2, 2001

Appl. No.:

09/898533

Inventors:

Robert Gemmill - Englewood CO, US
Harry Drabkin - Denver CO, US

International Classification:

C12Q001/68
C07H021/04
C12N009/00
C12P021/02
C12N005/06

US Classification:

435/006000, 435/183000, 435/069100, 435/320100, 435/325000, 536/023200

Abstract:

The present invention provides the sequence for a novel gene called TRC8 which is located on chromosome 8. Various types of alterations in the gene have been shown to be associated with renal and thyroid tumors. One such alteration involves a 3;8 translocation which interrupts TRC8 and results in a fusion with the 3p14 gene, FHIT. Another alteration includes a mutation in the 5′ untranslated region of TRC8. Thus, the invention further provides sequences corresponding to the gene fusions created during the translocation, as well as the sequence of the gene containing the mutation in the 5′ region. The invention further provides methods for detecting alterations in TRC8 which have potential utility in the diagnosis of tumors.

US Patent:

20080182865, Jul 31, 2008

Filed:

Sep 25, 2007

Appl. No.:

11/861033

Inventors:

Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US

International Classification:

A61K 31/498
A61K 31/4406

US Classification:

51426624, 514357

Abstract:

Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

US Patent:

20080234265, Sep 25, 2008

Filed:

Mar 13, 2006

Appl. No.:

11/908388

Inventors:

Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Steamboat Springs CO, US
Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Daniel Chuen-Fong Chan - Denver CO, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO

International Classification:

A61K 31/16
A61K 31/19
A61K 31/27
A61K 31/395
A61K 31/5377
A61K 31/517
C12Q 1/68

US Classification:

5142345, 514575, 514557, 514487, 514183, 5142664, 435 6

Abstract:

Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.

US Patent:

20110294686, Dec 1, 2011

Filed:

Sep 11, 2009

Appl. No.:

13/063260

Inventors:

Harry A. Drabkin - Charleston SC, US
Robert M. Gemmill - Charleston SC, US
Federico R. Cappuzzo - Denver CO, US
Wan Lam - Vancouver, CA

International Classification:

C40B 30/04
C12Q 1/68
C40B 40/06

US Classification:

506 9, 506 16, 435 611

Abstract:

Disclosed is the identification, provision and use of biomarkers predictive of sensitivity or resistance to EGFR inhibitors such as gefitinib and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the copy number or expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

US Patent:

20120141479, Jun 7, 2012

Filed:

Jul 23, 2008

Appl. No.:

12/670053

Inventors:

Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Evergreen CO, US
Harry A. Drabkin - Denver CO, US
Robert M. Gemmill - Centennial CO, US
Daniel Chan - Denver CO, US

International Classification:

A61K 39/395
A61P 35/00
A61K 31/404
A61K 31/343
A61K 31/496
A61K 31/517
A61K 31/4406
A61K 38/12

US Classification:

4241341, 514357, 514 199, 514469, 51425218, 51426624, 514414, 4241741, 4241331, 514 194

Abstract:

Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

US Patent:

62681761, Jul 31, 2001

Filed:

Mar 12, 1999

Appl. No.:

9/268140

Inventors:

Robert M. Gemmill - Englewood CO
Harry A. Drabkin - Denver CO

Assignee:

University Technology Corporation - Boulder CO

International Classification:

C12P 2106
C12P 1934
C12Q 168
A61K 3800
C07K 100

US Classification:

435 691

Abstract:

The present invention provides the sequence for a novel gene called TRC8 which is located on chromosome 8. Various types of alterations in the gene have been shown to be associated with renal and thyroid tumors. One such alteration involves a 3;8 translocation which interrupts TRC8 and results in a fusion with the 3p14 gene, FHIT. Another alteration includes a mutation in the 5' untranslated region of TRC8. Thus, the invention further provides sequences corresponding to the gene fusions created during the translocation, as well as the sequence of the gene containing the mutation in the 5' region. The invention further provides methods for detecting alterations in TRC8 which have potential utility in the diagnosis of tumors.